Utility of Intermediate Risk Volumes in Human Papilloma Associated Oropharyngeal Cancer: A Pattern of Failure Analysis
G.Q. Yang(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Michelle Echevarria(Moffitt Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
March 11, 2022
Cited by 1
Related Papers
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
|International Journal of Radiation Oncology*Biology*Physics|2023|18
A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
|Annals of Oncology|2019|5
NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study
|International Journal of Radiation Oncology*Biology*Physics|2020|4
Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles From Patients with HPV-Positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy
|International Journal of Radiation Oncology*Biology*Physics|2022|2